A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Fountain Valley, California 92708, United States
Irvine, California 92697, United States
New Brighton, Minnesota 55112, United States
Murfreesboro, Tennessee 37129, United States
Toon-Shi, Ehime 7910295, Japan
Nakoku, Kochi 783-8505, Japan
Itabashi-Ku, Tokyo 173-8606, Japan
Itabashi-ku, Tokyo 173-8610, Japan
Minato-ku, Tokyo 105-8471, Japan
Shinagawa, Tokyo 141-8625, Japan
Shinjuku-Ku, Tokyo 160-0023, Japan
Krak, 30-510, Poland
Moscow, 111398, Russia
Ryazan, 390046, Russia
Saint Petersburg, 194021, Russia
Lancashire, FY2 0JH, United Kingdom